Suntar Eco-City Ltd. Reports Revenue Growth
Haw Par's (SGX:H02) Dividend Will Be SGD0.20
Haw Par Announces Board Restructuring
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Tianfeng Securities released a research report on April 19 stating that Daren Tang (600329.SH) was rated to increase its holdings. The main reasons for the rating include: 1) the “three core and nine wings” strategy is progressing steadily, with significa
Tianfeng Securities released a research report on April 19 stating that Daren Tang (600329.SH) was rated to increase its holdings. The main reasons for the rating include: 1) the “three core and nine wings” strategy is progressing steadily, with significant growth in core products; 2) steady improvement in profitability; and 3) impressive growth in overseas markets. (Mainichi Keizai Shimbun)
Pharmesis' Attributable Loss for 2023 Widens
Pharmesis (SGX:BFK) booked an attributable loss to equity holders of 5.0 million yuan in the year ended Dec. 31, 2023, compared with 3.6 million yuan in the year-ago period, according to an annual rep